title: Twice-weekly high-dose rHuEpo for the treatment of anemia in patients with low-risk myelodysplastic syndromes.
authors.affiliation: Department of Cellular Biotechnology and Hematology, University La Sapienza, Rome, Italy. rob.lati@libero.it
authors.forename: R
authors.initials: R
authors.lastname: Latagliata
authors.forename: E N
authors.initials: EN
authors.lastname: Oliva
authors.forename: P
authors.initials: P
authors.lastname: Volpicelli
authors.forename: I
authors.initials: I
authors.lastname: Carmosino
authors.forename: M
authors.initials: M
authors.lastname: Breccia
authors.forename: I
authors.initials: I
authors.lastname: Vincelli
authors.forename: C
authors.initials: C
authors.lastname: Alati
authors.forename: L
authors.initials: L
authors.lastname: Napoleone
authors.forename: F
authors.initials: F
authors.lastname: Vozella
authors.forename: F
authors.initials: F
authors.lastname: Nobile
authors.forename: G
authors.initials: G
authors.lastname: Alimena
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000740:Anemia / Q000188:drug therapy*; D020732:Cytogenetic Analysis; D004921:Erythropoietin / Q000008:administration & dosage* / Q000633:toxicity; D005260:Female; D006454:Hemoglobins; D006801:Humans; D008297:Male; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000150:complications* / Q000188:drug therapy; D011994:Recombinant Proteins; D016896:Treatment Outcome
chemical_list: D006454:Hemoglobins; D011994:Recombinant Proteins; D004921:Erythropoietin